US FDA’s Overloaded Advanced Therapies Office Eyes Organizational, Communication Changes
Executive Summary
Office of Tissues and Advanced Therapies seeks to optimize its organizational structure and adopt more group-level communications, instead of one-on-one interactions with sponsors, to keep up with the massive growth in cell and gene therapies, director Wilson Bryan says.
You may also be interested in...
US FDA’s Gene Therapy Office Director Nicole Verdun Must Fill Other Roles As Well
Until hiring is completed, the new Office of Therapeutic Products director must head an office and two divisions she supervises in addition to her actual duties.
US FDA’s Cell/Gene Therapy Office Looks To Improve Clarity Of Advice Through Written Responses
Standardizing the process for providing clarifications following sponsor meetings, particularly with regard to the written response-only format, is one of several solutions being piloted by the Office of Tissues and Advanced Therapies as part of its ‘growth program,’ which aims to expedite advances in cell/gene therapies while also improving staff satisfaction.
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule
The upcoming review of two novel gene therapies from bluebird bio marks will be the first time the US FDA’s CTGTAC has met for a genetic product review in five years. That is a surprisingly long gap – and one that probably will not be repeated.